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1. Introduction
Premature  death  connected  mainly  with  somatic  disorders  is  observed  among  patients
with  schizophrenia.  The  major  reason  for  this  phenomenon  are  metabolic  disorders
caused on the one hand by side effects of pharmacological treatment [1], on the other by
genetically  determined  differences  in  metabolism.  Finally,  the  importance  of  behavioral
factor,  which  is  the  lifestyle  of  patients  with  schizophrenia,  must  not  be  ignored  here.
Obesity, physical inactivity, poor diet, and smoking are the major factors contributing to
the development and intensification of  cardiovascular  diseases.  These factors  are  so im‐
portant  because  they  can  be  modified,  as  opposed  to  the  genetic  factors  or  necessary
pharmacological treatment.
This article addresses the issue of nicotine addiction among patients with schizophrenia.
1.1. Schizophrenia and nicotine addiction
1.1.1. Scope of phenomenon
The phenomenon of tobacco dependence involves 60-90% of patients with schizophrenia,
and it is a much higher rate than among the general population, where the percentage of
smokers varies between 25-47% [2-6].
A  study  by  de  Leon  et  al.  [7]  and  Gurpegui  et  al.  [8]  has  shown  that  in  adults  (over
twenty years  old)  who are  in  the  group of  increased susceptibility  to  schizophrenia,  or
are  already  suffering  from  the  disease  there  is  a  significantly  higher  risk  of  taking  up
smoking  than  among  the  general  population  [9].  No  wonder  then  that  the  problem  of
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nicotine  addiction  and  its  consequences  is  becoming  more  and  more  urgent  in  clinical
psychiatry.
Schizophrenics are most often among the so-called heavy smokers, which means, first of all,
smoking at least 20 cigarettes a day, and often a shorter interpuff interval, and smoking cig‐
arettes with a higher nicotine content [3, 10].
In  this  group  of  patients  a  higher  risk  of  dependence  on  nicotine  is  observed  [11],  as
well  as  a  more severe abstinence syndrome when trying to quit  smoking [12].  This  last
phenomenon probably results from the fact that in schizophrenics there are, independent
of  metabolism,  higher  levels  of  nicotine  and  cotinine  than  in  the  blood  of  non-schizo‐
phrenics  smoking the  same amounts  of  cigarettes  [13].  This  fact  can  be  explained by  a
greater  number  of  puffs  per  cigarette  and shorter  interpuff  intervals  [10].  It  is  not  sur‐
prising, therefore, that schizophrenics stop smoking more rarely than non-psychotic peo‐
ple  [14],  and the  treatment  of  nicotine  addiction  -  behavioral  and pharmacological  -  in
this group is much less effective [15-18].
1.1.2. Health consequences of smoking in schizophrenics
Research shows that patients suffering from schizophrenia live roughly 20% shorter than
healthy people, while cigarette smoking is here one of the main risk factors for premature
death [19]. It was also shown that due to smoking these patients die on average 10 years ear‐
lier than the general population [20, 21].
This increased mortality is largely the result of cancer, cerebrovascular disease, respiratory
diseases, and coronary heart disease. It is estimated that approximately 33% of psychotic pa‐
tients suffer from this illness and in this group it accounts for more premature deaths than
suicide [22].
This phenomenon is particularly relevant in the light of reports which indicate that in schiz‐
ophrenics who smoke regularly there is a higher risk of coronary heart disease and stroke
than in the general population [23]. It is estimated that, in the group with schizophrenia, the
risk of death from cardiovascular problems is about 2.2 times higher than among the general
population [24].
Also, in schizophrenia patients, respiratory diseases [25, 26] such as chronic obstructive pul‐
monary disorder (COPD) and pneumonia are frequently observed. Although lung cancer
occurs less frequently in patients with schizophrenia than among the general population,
the effects of cigarette smoking are clearly seen here [27]. In the case of COPD and lung can‐
cer, cigarette smoking is undoubtedly a significant etiologic factor [28]. Smoking can also in‐
crease susceptibility to pneumonia [29]. As shown in the Copeland et al. [26] study, COPD
and pneumonia are the diseases more frequently occurring in the last year of life in schizo‐
phrenics than in those mentally healthy. In this group of patients the risk of dying from res‐
piratory diseases is estimated to be approximately 3.2 times higher than among the general
population [30].
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1.1.3. Biological determinants of smoking
1.1.3.1. Genetic background
The empirical data available suggest the existence of common risk factors for schizophrenia
(and other mental illnesses) and smoking. The possibility of a genetic risk factor, particularly
associated with the regulation of cholinergic neurotransmission is emphasized here [31-35].
1.1.3.2. Self-medication hypothesis
Self-medication hypothesis is based on the assumption that the use of psychoactive substan‐
ces helps patients compensate for neurobiological deficits underlying a variety of ailments
[36, 37]. Accordingly, intuitive reaching for cigarettes by schizophrenics would facilitate
both dealing with the symptoms of the disease – positive and negative or with cognitive im‐
pairment, as well as with the side effects of treatment.
However, the importance of smoking in coping with the disease symptoms is not clear [38].
Some studies show an improvement within the range of negative symptoms by increasing
the dopamine release in the prefrontal cortex [39-42]. These results, however, are subject to a
number of constraints - sample size and methodological limitations. It is also worth remem‐
bering that research on animal models indicated that while occasional acute administration
of nicotine did increase the dopamine release in the brain, chronic administration of nicotine
resulted in a decrease in dopamine level, but these effects varied in different areas of the
brain [41-43].
There is more data on the relief of drug-induced symptoms and on the cognitive deficits.
1.1.3.2.1. Neuroleptics
Referring the self-medication hypothesis to the problem of antipsychotic treatment [38], it
should be assumed that smoking helps to reduce the adverse symptoms of antipsychotic
treatment. The mechanism that may explain the reduced severity of extrapyramidal symp‐
toms associated with high-dose neuroleptic treatment, may be the nicotine-induced acceler‐
ation of drug metabolism by cytochrome P450 (CYP1A2, CYP2D6 polymorphisms) [4, 44].
Thus alleviation of drug induced effects of the CYP1A2 metabolized neuroleptics can be ex‐
pected but there should be no such effects in case of drugs metabolized in a different way.
The empirical data do not provide conclusive evidence that heavy smoking has a really im‐
portant role in alleviating the side effects of antipsychotic treatment, especially such as tar‐
dive dyskinesis or akathisia [38].
Antipsychotic drugs with anticholinergic properties influence the expression of nicotine ace‐
tylcholine receptors (nAChRs) [45]. This translates into a deterioration of neurotransmission
in the cholinergic system in patients with schizophrenia.
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1.1.3.2.2. Cognitive factors – The role of the cholinergic system
The cholinergic neurotransmission is one of the key phenomena important for cognitive
functioning. This applies in particular to such areas of the brain as the prefrontal cortex and
hippocampus, whose functions are regulated by cholinergic projections from other parts of
the brain [46]. Cholinergic system dysfunction is manifested, among others, in impaired cog‐
nitive functions such as memory and attention disorders. On the other hand stimulation of
this system results in memory improvement.
Research shows that administration of nicotine to schizophrenics, both smokers and non-
smokers, activating the cholinergic system, reduces the cognitive deficits connected with e.g.
working memory, attention, and spatial organization [47-49].
It was also observed that in schizophrenics cognitive deficits worsen with the increase of
withdrawal symptoms, and restarting smoking alleviates these unwanted changes in cogni‐
tive functioning [49]. This suggests that the treatment of cognitive deficits connected with
schizophrenia could contribute to increasing the chance of successful smoking cessation,
and indirectly to improving the patient’s overall health.
1.1.4. Psychological determinants of smoking
As shown above, in a group of schizophrenics there are a number of biological factors, spe‐
cific to a lesser or greater extent to schizophrenia which explain the increased incidence of
nicotine dependence in this group of patients. However, these factors are not the only ones
that are relevant here. The psychosocial factors should not be ignored, especially that these
factors are largely modifiable, and thus possible to be included in a therapeutic process.
Many reasons for smoking, mentioned by patients suffering from schizophrenia, are similar
to those mentioned by healthy people. Some of the common arguments are: pleasure, addic‐
tion, weight control, the need for relaxation, or a desire to calm down.
Schmitz et al. [50] presume the possibility of an increased susceptibility to nicotine addiction
in people who have difficulty coping with stress, tension, anxiety, or depression. Anxiety
and depressive disorders have been repeatedly identified as a risk factor for taking up and
continuing smoking [51]. In psychotic patients, the coexistence of these various disorders
can further increase the tendency to smoking.
Patients with schizophrenia often emphasize that cigarettes are for them a product of first
necessity, just like food, and help them endure life with the illness and prevent schizophre‐
nia relapses [52]. Not without reason, therefore, schizophrenics often mention the sedative
effect of nicotine as the main reason for smoking [38]. This temporary way of dealing with
unpleasant symptoms, however, puts in motion a vicious circle, because the inability to
cease smoking is also the cause of stress and can lead to a greater anxiety than in the begin‐
ning. After lighting a cigarette waiting for the calming effect is also important. However, in
many cases of agitation, such an effect does not appear, which results in smoking more and
more cigarettes in the hope that a higher dose of nicotine will eventually help [38].
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Schizophrenics often emphasize that smoking is the fulfillment of a strong need related to
addiction, it is also an opportunity to escape and helps to control emotions. In Solway et al.
clinical studies [53] the psychotic patients singled out three main roles that smoking plays in
their daily functioning. Smoking is a tool used to control stress, helps to make interpersonal
contacts and meet the need for peace and comfort. Facilitating interpersonal relations occurs
here by entering a group of smokers, which helps to cope with the sense of exclusion and of
being different (tobacco use is thus understood as supporting the development of social net‐
works and a source of social support). Solway et al. [53], however, draw attention to the fact
that the respondents are increasingly aware of the fact that smoking - contrary to expecta‐
tions - does not accomplish its purpose in terms of interpersonal contacts. Although many of
the schizophrenics examined began to smoke in order to reduce discomfort in social situa‐
tions, there is currently a trend towards unfavorable attitudes to smokers, which, in individ‐
uals suffering from mental illnesses, may create an additional barrier in the process of
socializing.
People suffering from schizophrenia find it more difficult to quit smoking partly because of
the withdrawal symptoms, including irritability, poor concentration, impatience and anxiety
[6], and partly because they do not have enough support and motivation to do it successful‐
ly. The balance of gains and losses related to smoking cessation is in favor of the benefits of
tobacco use [53]. The decision to maintain the addiction is often connected with the opinions
functioning in society (especially among relatives), suggesting many obstacles and losses re‐
sulting from the process of smoking cessation.
According to de Leon et al. [54] the socio-economic status and poor education about the neg‐
ative effects of smoking have a major impact on the initiation of smoking in people with se‐
vere mental illnesses. De Leon et al. [54] also suggest that in some countries where tobacco
use by women is prohibited, the relationship between smoking and schizophrenia cannot be
proven. This points to the fact that the number of cigarettes smoked by people with schizo‐
phrenia depends on their availability [54]. In Poland, the price of cigarettes is relatively high
compared to the income of the mentally ill. However, patients cope with these economic
constraints by selecting the cheapest cigarettes, usually without a filter, from illegal sources,
or they roll the cheap tobacco cigarettes. Also, the surrounding people often provide the pa‐
tient with cigarettes. In the Solway’s research [53] some smokers suffering from severe men‐
tal illnesses stated that the reason for their initiation of smoking was the addiction of one of
their family members or friends.
In the Solway’s research [53], some respondents answered that they do not feel the need for
smoking when cigarettes are not in sight, but at the time of distress, anxiety, or in a situation
where there is a person smoking nearby, they feel a strong desire to smoke a cigarette.
Meanwhile, in Poland, the functioning of patients is often based on life in communities
which are dominated by smokers. Many smokers define the sole physical act of holding a
cigarette as a highly satisfactory form of relaxation.
In conclusion, a number of biological and psychosocial phenomena are observed in patients
with schizophrenia that exacerbate the problem of nicotine addiction and hinder the process
of smoking cessation. A better understanding of the mechanisms associated with cigarette
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smoking in this group of patients may help to improve their quality of life, their general
health, but also reduce the economic effects associated with the treatment and the conse‐
quences of tobacco-related diseases in schizophrenics.
1.1.5. Aim of the research
The research was designed to characterize nicotine dependence in schizophrenics compared
to smokers not having mental health problems. Indirectly, the research was also to deter‐
mine whether the affective psychological factors such as anxiety or depression and the level
of distress are important predictors of smoking in a group of psychotic patients.
2. Material and methods
2.1. Participants
204 smokers participated in the research, including 104 people with paranoid schizophrenia
and 100 healthy persons. The schizophrenic smokers recruited for the research were in re‐
mission of psychotic symptoms or had residual symptoms and their condition was stable.
These people have been treated for schizophrenia for at least 1 year. The control group were
smokers who have not been diagnosed with a serious mental or somatic illness. At the time
of the research, all the participants were in the active phase of nicotine dependence.
2.2 Design of research
The research was cross-sectional and was carried out in Mental Health Outpatient Clinics
and Psychiatric Day Hospitals. The control group, consisting of mentally healthy people,
was recruited in the Occupational Medicine Outpatient Clinics, where they came for period‐
ic employee medical examinations. The research participants underwent a structured inter‐
view concerning smoking, and then the respondents were asked to complete five self-report
questionnaires.
2.3. Tools
2.3.1. Interview
The interview with the respondents concerned their smoking history and included ques‐
tions about the time of smoking initiation, the addiction process over time, the daily rituals
related to smoking, number of attempts to stop smoking, length of periods of abstinence, the
average number of puffs per cigarette, and the type of cigarettes smoked. Also, in the inter‐
view information was obtained about basic socio-demographic data, such as economic sta‐
tus, family, place of residence. In the case of patients with schizophrenia the interview
contained additional questions about the course of the disease and its treatment.
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2.3.2. Fagerström test for nicotine dependence
The study used the Fagerström Test for Nicotine Dependence (FTND) in order to estimate
the severity of nicotine dependence [55]. This tool consists of 8 questions concerning factors
associated with smoking. The result obtained is in the range of 0-11 points. The 0-4 points
result corresponds to a low degree of dependence, 5-7 points – to a high degree, and the re‐
sult of more than 7 points corresponds to a very high dependence. Although Steinberg et al.
[56] demonstrated that, in the schizophrenic group, this tool carries the risk of underestimat‐
ing the size of the problem, yet, in this study, the introduction of a detailed interview is an
attempt to compensate for these deficiencies.
2.3.3. The test of motivation for smoking cessation
The test of motivation for smoking cessation consists of 12 items containing statements
about the smoker dependent factors that contribute to smoking cessation (e.g., Do you decide
to quit smoking for yourself?, Do you know why you smoke?, Do you know how to cope in crisis
situations?). The respondent gave his own answers to these items by indicating whether the
statement referred to him or not. The Cronbach's α coefficient for this scale is 0.91. Predomi‐
nance of positive responses (> = 6 points) corresponds to a relatively strong motivation to
smoking cessation.
2.3.4. The test of readiness to change
This tool has been designed on the basis of the Transtheoretical Model of Behavioral Change
(TTM) [57] assumptions. According to this model, the current smokers are at the stage of
precontemplation, contemplation or preparation. The precontemplation stage is defined as
the lack of need for changes in behavior. At the stage of contemplation an intention to
change behavior within the next 6 months emerges (here: to stop smoking) (but making this
change is not planned within the next 30 days). And finally, the preparation stage is referred
to as planning changes within the next month and attempts to stop smoking (lasting a mini‐
mum of 24 hours) can be indicated in the past year [58].
The Test of Readiness to Change used in this research consists of 8 questions, making it pos‐
sible to identify persons at the stage of precontemplation, contemplation, preparation, and
action (i.e. the act of smoking cessation).
2.3.5. Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale (HADS) is a widely used, short, 14 item tool
for  studying  anxiety  and  depression  [59].  Each  of  the  tool  subscales  consists  of  seven
statements  to  which  the  tested  person  responds  on  a  four  point  scale,  where  0  corre‐
sponds to no intensity or  to the weakest  intensity of  a  given symptom, and 3 indicates
the presence of a severe symptom.
This questionnaire was initially recommended as an ambulatory screening tool, but is now
also commonly used to assess symptoms of depression and anxiety in different groups of
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patients [60]. The sensitivity and specificity of this tool is satisfactory and is about 0.8 [61]. In
our study, the scale reliability (Cronbach's α coefficient) was 0.86 for the depression subscale
and 0.87 for the anxiety scale, which is consistent with the results obtained by other re‐
searchers [62, 63].
2.3.6. Distress thermometer
The Distress Thermometer is a single item screening tool that allows a subjective assessment
of the severity of distress in the recent time. The respondent marks, on a scale of 0 to 10, how
high was the level of stress he or she experienced during the last week. The validation stud‐
ies of the Polish version of the tool have shown that the 4 point or more result indicates a
high risk of comorbid depression and / or anxiety [64].
3. Results
The demographic characteristics of the respondents are shown in Table 1. The schizophren‐
ics were more often single people, less educated, unemployed, and of worse financial situa‐
tion than those in the control group.
Table 2 presents the comparison of the schizophrenics and the control group in terms of
smoking.
The psychotic  patients  smoked more,  took a  greater  number  of  puffs,  showed a  higher
level  of  dependence  and  were  less  motivated  to  give  up  smoking  than  the  mentally
healthy persons.
It was also observed that the schizophrenics taking atypical medications (n = 58), smoked
less and took puffs less frequently than those treated with conventional drugs (n = 46). There
were no differences between the groups with respect to the age of smoking initiation (first
cigarette), while the schizophrenics started smoking on a daily basis earlier than the healthy
individuals. Those in the control group made attempts to quit smoking more often, and
their abstinence periods were longer. It was also observed that as the period of being ill with
schizophrenia gets longer, the number of cigarettes smoked grows (r = 0.16, p <0.05) and the
level of dependence increases (r = 0.31, p <0.01).
Most schizophrenics had no intention to quit smoking, while people in the control group
were more often at the contemplation or preparation stage for smoking cessation (Table 3).
Other motives for smoking cessation were also shown. In the mentally healthy individuals
the major motive was their relatives’ pressure, the desire to save money and, to a lesser ex‐
tent, the beginning of health problems. The dominant motive in the schizophrenics, howev‐
er, was the appearance of tobacco-related disease, manifested mainly by shortness of breath.
The rarest motive turned out to be the pressure of relatives.
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Smokers (N=204) Schizophrenics (N=104) Non-psychiatric (N=100)
Gender [n(%)]
Male 61 (58.7) 54 (54.0)
Female 43 (41.3) 46 (46.0)
Age [years]
Mean (SD) 44.31 (13.94) 44.02 (11.40)
Range 20 – 67 20 – 65
Marital status [n(%)]
Single 32 (30.8) 25 (25.0)
Married 39 (37.5) 48 (48.0)
Widowed 13 (12.5) 15 (15.0)
Divorced 20 (19.2) 12 (12.0)
Level of education [n(%)]
Primary 29 (27.9) 5 (5.0)
Vocational 54 (51.9) 35 (35.0)
Secondary 20 (19.2) 42 (42.0)
Higher 1 (1.0) 18 (18.0)
Residence[n(%)]
With family 54 (52.0) 59 (59.0)
Alone 15 (14.4) 41 (41.0)
In a nursing home 35 (33.6) -
Financial Situation [n(%)]
Poor 60 (57.7) 18 (18.0)
Average 31 (29.8) 56 (56.0)
Good 13 (12.5) 26 (26.0)
Employment status [n(%)]
Employed 18 (17.3) 69 (69.0)
Unemployed 23 (22.1) 16 (16.0)
Disability Pension 50 (48.1) 9 (9.0)
Retirement 13 (12.5) 6 (6.0)
Table 1. Socio-demographic characteristics of the smokers with schizophrenia and non-psychiatric controls.
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Smoking Schizophrenics(N=104)
Non-psychiatric
(N=100)
Comparisons
t
Cigarettes
Cigarettes smoked per day [M(SD)] 25.98 (13.40) 20.09 (8.58) 3.72***
Range [n (%)]
1-10 14 (13.5) 20 (20.0)
11-20 42 (40.4) 46 (46.0)
21-30 28 (26.9) 30 (30.0)
"/>30 20 (19.2) 4 (4.0)
Nicotine yield of cigarettes [M(SD)] 1.03 (0.22) 0.85 (0.22) 5.97***
Puffs per cigarette [M(SD)] 12.12 (3.57) 8.64 (2.39) 8.14***
Min to first cigarette of the day [M(SD)] 7.23 (4.58) 7.54 (3.97) 0.36
Nicotine dependence
FTND [M(SD)] 7.63 (2.62) 6.30 (1.95) 4.12***
Years of daily smoking [M(SD)] 23.87 (14.26) 24.35 (12.02) -0.26
Age of first smoking [M(SD)] 17.00 (4.49) 17.31 (5.59) 0.43
Age of daily smoking [M(SD)] 19.67 (3.84) 20.44 (8.53) 0.83
Smoking cessation
Motivation to quit [M(SD)] 5.47 (3.54) 8.39 (2.24) -7.07***
Past quit attempts [M(SD)] 2.05 (1.78) 3.92 (3.04) -5.34***
Longest abstinence period [months] [M(SD)] 3.39 (4.55) 5.52 (6.18) -2.80**
Notes: ** p<0.01; *** p<0.001
FTND – Fagerström Test for Nicotine Dependence
Table 2. Smoking characteristic of schizophrenic patients and healthy participants.
Stage of change Schizophrenics ( N =104)n (%)
Non-psychiatric ( N =100)
n (%)
Precontemplation 61 (58.6) 29 (29.0)
Contemplation 35 (33.7) 46 (46.0)
Preparation 8 (7.7) 25 (25.0)
Table 3. Readiness to smoking cessation
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In the schizophrenics a higher level of distress and anxiety was observed than in the control
group. Depression of the psychotic patients was also higher than in the healthy persons, but
the difference did not reach statistical significance (table 4).
Factors
Schizophrenics (N=104) Non-psychiatric
(N=100)
Comparisons
tsubgroups M (SD)
Anxiety
all 9.20 (4.43)
6.28 (3.44)
5.28***
typical treat. 9.49 (4.27)a 5.70***
atypical treat. 7.50 (5.97)a 2.68
Depression
all 7.48 (3.65)
6.56 (3.10)
1.94
typical treat. 7.53 (3.72) 2.01
atypical treat. 6.87 (3.10) 0.68
Distress
all 5.42 (2.64)
4.20 (2.37)
3.47**
typical treat. 5.67 (2.67)b 3.64***
atypical treat. 5.31 (1.92)b 2.79*
Notes: * p<0.05; ** p<0.01; *** p<0.001
typical treat. – typical neuroleptics (n=46)
atypical treat. – atypical neuroleptics (n=58)
a comparison between typical and atypical treatment subgroups: t=4.32 (p<0.001)
b comparison between typical and atypical treatment subgroups: t=2.15 (p<0.05)
Table 4. Level of anxiety, depression and distress among participants
In  the  subgroup  of  schizophrenics,  in  the  patients  treated  with  atypical  neuroleptics,  a
lower level of distress appeared (but still  significantly higher than in the control group)
and anxiety.
The analysis of the correlation between the affective factors and distress and the parameters
characterizing smoking, indicated that in both groups – in the schizophrenics and in the con‐
trol group - higher levels of anxiety, depression and distress are associated with a greater
number of cigarettes smoked (table 5).
To determine the predictive power of the affective factors and distress for the number of cig‐
arettes smoked multivariate linear regression analysis was carried out (table 6).
Affective factors and distress explain a greater percentage of variance of the number of ciga‐
rettes in the group of mentally healthy persons (adj.R2 = 0.56) than in the group of schizo‐
phrenics (adj.R2 = 0.34).
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Smoking Anxiety Depression Distress
Schizophrenic patients
Cigarettes smoked per day 0.57*** 0.64*** 0.67***
-0,04Puffs per cigarette -0.07 -0.03
Nicotine dependence (FTND) 0.53*** 0.49*** 0.55***
Motivation to quit -0.02 0.04 0.13
Non-psychiatric participants
Cigarettes smoked per day 0.56*** 0.21* 0.62***
Puffs per cigarette 0.12 -0.01 0.07
Nicotine dependence (FTND) 0.55*** 0.17 0.53***
Motivation to quit -0.14 -0.02 -0.06
Notes: * p<0.05; *** p<0.001
FTND – Fagerström Test for Nicotine Dependence
Table 5. Correlation between the affective factors and distress and the parameters characterizing smoking.
Factors
Schizophrenic patients
(N=104)
Non-psychiatric smokers
(N=100)
adj.R2=0.34 adj.R2=0.56
β ΔR2 β ΔR2
Anxiety 0.14 0.04 0.48*** 0.24
Depression 0.36** 0.11 0.18 0.05
Distress 0.47*** 0.19 0.55*** 0.27
Notes: ** p<0.01; *** p<0.001
Table 6. Predictors of numbers of cigarettes smoked per day (multivariate linear regression model).
In both groups, the strongest predictor of smoking was distress and the predictive power of
anxiety and depression was distributed differently in the group of schizophrenics and the
control group. In the mentally ill patients depression was more strongly correlated with
smoking, and in the control group, a stronger correlation with the number of cigarettes
smoked was observed for anxiety.
4. Discussion
The  study  confirmed  the  observations  of  other  researchers  that  schizophrenics  smoke
more  than  the  mentally  healthy  and  take  a  greater  number  of  puffs  per  cigarette  [10,
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65].  In  the group of  mentally  ill  patients,  similarly as  in  the Tidey et  al.  [10]  studies,  a
variation  in  the  number  of  cigarettes  smoked  and  the  number  of  puffs  taken  was  ob‐
served depending on the type of  treatment  applied.  The fact  that  patients  taking atypi‐
cals  smoked  less  than  the  patients  receiving  typical  medication,  may  result  from  the
different  effect  of  taking  these  drugs.  Several  studies  have  shown  that  atypical  drugs
such as clozapine and olanzapine, are conducive to reducing smoking, reduce the desire
to  smoke  and,  finally,  relieve  the  withdrawal  symptoms  [10,  66,  67].  Also,  in  patients
taking atypicals,  a lower level  of  distress is  observed [68].  In this study, distress turned
out to be a significant predictor of smoking, therefore it  is possible that this mechanism
is important in explaining the observed difference. In the presented work, however, nei‐
ther  the  timing nor  the  doses  of  the  administered medication were  controlled,  so  these
dependencies are worth researching more closely in the future.
The analysis of the factors motivating schizophrenics to stop smoking indicates a very seri‐
ous problem. Only a significant deterioration of health, to be precise, shortness of breath
making smoking impossible, inclined patients to consider reducing or giving up smoking.
Lack of finances and bans on smoking in public places and in the place of residence were
not a sufficient bareer for people with schizophrenia. Lack of pressure from the close envi‐
ronment to reduce smoking should also be noted. This may result from the fact that the clos‐
est people here are often smokers themselves (often these are other patients). Interviews
with the patients showed that most often it was the family who supplied the patients with
cigarettes, and thus contributed to continuing this addiction in schizophrenics.
The results of the study show the important role of affective factors and a feeling of dis‐
tress in nicotine dependence. This importance is greater in the group of healthy persons
than in schizophrenics, but the results obtained in this study (26% of the explained var‐
iance  of  the  number  of  cigarettes  smoked)  suggest  introducing  psychological  (and/or
pharmacological)  interactions,  aimed at  improving  coping  with  stress  and  reducing  the
negative affect. These results also confirm the fact that cigarette smoking in schizophren‐
ics  is  probably,  to  a  much  greater  extent  than  in  the  mentally  healthy,  determined  by
factors other than affective [31-37].
The study also confirmed a significant relationship between distress and the number of ciga‐
rettes smoked. These results are consistent with other studies. It should be noted, that dis‐
tress may have different sources and may be understood differently by the respondents. It is
therefore a very general construct, and in this study should be understood as the so called
aggregate variable [69].
5. Conclusion
The relationship between distress, affective factors, and cigarette smoking has important
clinical implications. First of all - apart from the typical pharmacological treatment and nico‐
tine replacement therapy – psychological treatment should be implemented into programs
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for nicotine dependence to improve the functioning of schizophrenics in terms of coping
with stress and maintaining good mood.
Secondly, it seems interesting to study the causes of the perceived distress. Knowing the
sources of stress and the strategies of coping with it can help to build more effective pro‐
grams supporting the treatment of nicotine addiction.
Weak pressure of the environment on the mentally ill to quit smoking, and even strengthen‐
ing the addiction by the closest ones, points to a need for actions targeted at the schizo‐
phrenics’ environment. Such interventions should be aimed at increasing the knowledge
about smoking and its consequences, including families in the process of motivating to quit
smoking and improving support given to patients.
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